There are 2789 resources available
1041MO - 5-year update on COLUMBUS: A randomized phase III trial of encorafenib (enco) + binimetinib (bini) versus enco or vemurafenib (vem) in patients (pts) with BRAF V600-mutant melanoma
Presenter: Reinhard Dummer
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA67 - Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Updated results from the phase III COSMIC-311 trial and prespecified subgroup analyses by prior therapy
Presenter: Jaume Capdevila
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1743MO - MERAIODE: A redifferentiation phase II trial with trametinib followed by radioactive iodine for metastatic radioactive iodine refractory differentiated thyroid cancer patients with a RAS mutation
Presenter: Sophie Leboulleux
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1099MO - Durvalumab plus tremelimumab influence on response to subsequent treatments in patients with neuroendocrine neoplasms (NENs) of gastroenteropancreatic and lung origins: Results from the phase II DUNE trial (GETNE 1601)
Presenter: Jorge Hernando
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1100MO - Molecular characteristics of high-grade gastroenteropancreatic neuroendocrine neoplasms
Presenter: Halfdan Sorbye
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
1101MO - Development of CAR T-cells for future treatment of NETs
Presenter: Barbara Mandriani
Session: Mini oral session - NETs and endocrine tumours
Resources:
Abstract
Slides
Webcast
347MO - 5-Aminolevulinic acid sonodynamic therapy in recurrent glioblastoma: A first-in-human phase 0/1 clinical trial
Presenter: Nader Sanai
Session: Mini oral session - CNS tumours
Resources:
Abstract
Slides
Webcast
LBA12 - Predictive value of gene-expression profiles (GEPs) and their dynamics during therapy in the NeoTRIPaPDL1 trial
Presenter: Giampaolo Bianchini
Session: Mini oral session - Breast cancer, early stage
Resources:
Abstract
Slides
Webcast
Introduction by the chair
Presenter: Edward Garon
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast
Consistent with regimens appropriate for initial treatment of metastatic disease
Presenter: Federico Cappuzzo
Session: Patients with metastatic progression on or shortly after durvalumab consolidation for stage III NSCLC should be treated
Resources:
Slides
Webcast